CARM — Carisma Therapeutics Share News
0.000.00%
Last trade - 00:00- $0.01m
- -$2.77m
- $19.63m
Carisma Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Carisma Therapeutics Inc expected to post a loss of 9 cents a share - Earnings Preview
Brief: Carisma Therapeutics And Orthocellix Enter Into Definitive Merger Agreement
Carisma Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary
Carisma Therapeutics Inc expected to post a loss of 10 cents a share - Earnings Preview
Carisma Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary
Brief: Carisma Therapeutics Provides Corporate Updates
Brief: Carisma Therapeutics Appoints Natalie Mcandrew As Principal Financial Officer
U.S. RESEARCH ROUNDUP- Altus Power, Marsh & Mclennan, TPI Composites
Brief: Carisma Therapeutics Announces Restructuring
Brief: Carisma Unveils Pre-Clinical Data On Anti-GPC3 In Vivo CAR-M Therapy For Hepatocellular Carcinoma
Carisma Therapeutics Inc reports results for the quarter ended in September 30 - Earnings Summary
Carisma Therapeutics Inc expected to post a loss of 26 cents a share - Earnings Preview
Brief: Carisma Therapeutics Announces Changes To Its Board Of Directors
Brief: Carisma Therapeutics Inc Got Notice Of Failure To Satisfy A Continued Listing Rule Or Standard From Nasdaq
Brief: Carisma And Moderna Expand Collaboration To Develop Two In Vivo CAR-M Therapies For Autoimmune Diseases
Carisma Therapeutics Inc reports results for the quarter ended in January - Earnings Summary
Carisma Therapeutics Inc expected to post a loss of 30 cents a share - Earnings Preview
Brief: Carisma Therapeutics On June 26, Notified Novartis Pharmaceuticals Of Termination Of Co's Manufacturing & Supply Agreement Between Co & Novartis